BNTC – benitec biopharma inc. (US:NASDAQ)

DELAYED


Volume Shares
1 Day Range
Volume Ratio
52 Week High
52 Week Low


VWAP
Today’s Volatility
20 Day Volatility
Open
Prior Close

YTD

1 Day

BNTC

SPY

QQQ

Swipe to see more

Main News & Impact Reports

Date

Time

Symbol

Headline

Impact

3/10

07:37 am

bntc

Benitec Biopharma to Host Industry Forum Breakfast Event at the 2026 Muscular Dystrophy Association Clinical and Scientific Conference on March 10, 2026, Highlighting Continued Progress for BB-301, the Only Clinical-Stage Therapeutic in Development for Oc

Medium Report

Report

3/10

07:00 am

bntc

Low Report

Report

3/9

04:05 pm

bntc

Benitec Biopharma (BNTC) had its "buy" rating reaffirmed by TD Cowen.

Low Report

Benitec Biopharma (BNTC) had its "buy" rating reaffirmed by TD Cowen.

Report

3/9

12:42 pm

bntc

Benitec Biopharma (BNTC) had its "buy" rating reaffirmed by HC Wainwright. They now have a $32.00 price target on the stock.

Low Report

Benitec Biopharma (BNTC) had its "buy" rating reaffirmed by HC Wainwright. They now have a $32.00 price target on the stock.

Report

3/9

07:32 am

bntc

Benitec Biopharma Announces Positive Interim Phase 1b/2a Results for High Dose BB-301 and Continued Durable Improvements for Low Dose BB-301 Treatment at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference [Yahoo! Finance]

Low Report

Report

3/9

07:00 am

bntc

Medium Report

Report

2/23

07:00 am

bntc

Benitec Biopharma Announces Acceptance of Late- Breaking Abstract for the BB-301 Phase 1b/2a Clinical Treatment Study at the Muscular Dystrophy Association Clinical & Scientific Conference

Low Report

Benitec Biopharma Announces Acceptance of Late- Breaking Abstract for the BB-301 Phase 1b/2a Clinical Treatment Study at the Muscular Dystrophy Association Clinical & Scientific Conference

Report

2/12

08:30 am

bntc

Benitec Biopharma Releases Second Quarter 2026 Financial Results and Provides Operational Update

Medium Report

Benitec Biopharma Releases Second Quarter 2026 Financial Results and Provides Operational Update

Report

1/31

04:42 am

bntc

Benitec Biopharma: BB-301's Early OPMD Data And Cash Infusion Justify A Bullish Upgrade [Seeking Alpha]

Low Report

Benitec Biopharma: BB-301's Early OPMD Data And Cash Infusion Justify A Bullish Upgrade [Seeking Alpha]

Report

1/12

12:02 pm

bntc

Benitec Biopharma (NASDAQ:BNTC) had its "buy" rating reaffirmed by analysts at Cowen Inc.

Low Report

Benitec Biopharma (NASDAQ:BNTC) had its "buy" rating reaffirmed by analysts at Cowen Inc.

Report

1/11

08:11 am

bntc

Benitec Biopharma Provides Positive Long-Term Clinical Study Results for BB-301 Phase 1b/2a Clinical Trial Demonstrating Robust Efficacy and Continued Durability of Response [Yahoo! Finance]

Low Report

Benitec Biopharma Provides Positive Long-Term Clinical Study Results for BB-301 Phase 1b/2a Clinical Trial Demonstrating Robust Efficacy and Continued Durability of Response [Yahoo! Finance]

Report

1/11

08:00 am

bntc

Benitec Biopharma Provides Positive Long-Term Clinical Study Results for BB-301 Phase 1b/2a Clinical Trial Demonstrating Robust Efficacy and Continued Durability of Response

Low Report

Benitec Biopharma Provides Positive Long-Term Clinical Study Results for BB-301 Phase 1b/2a Clinical Trial Demonstrating Robust Efficacy and Continued Durability of Response

Report

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.